Company Overview and News

0
An evening walk down Dalal Street: Global cues lift Sensex 277 pts ahead of Q1FY19 earnings

2018-07-09 moneycontrol
Equity benchmarks began the week on a strong note on Monday, gaining over 0.70 percent on positive global cues and ahead of June quarter earnings. Banks and metals stocks, and Reliance Industries, L&T and Infosys drove the market higher.
DB 500325 500820 JIPKY RELIANCE KTKBANK 532538 ASIANPAINT 532187 505283 RIGD UCLQY 500493 BHARATFORG RLNIY YESBANK INDUSINDBK KIRLPNU JPASSOCIAT UCLQF 532648 YYBKY STRTECH ULTRACEMCO 532532 SRLRY 532652 532374

0
Kirloskar Pneumatic surges 8% as board to consider stock split

2018-07-09 moneycontrol
Share price of Kirloskar Pneumatic Company surged 8 percent intraday Monday as company to consider stock split on July 24.
505283 KIRLPNU

14
Axis Bank, YES Bank, SBI Life results

2018-04-25 thehindubusinessline
Thursday will see a host of prominent companies, such as AB Money, Accelya Kale, AU Small Finance, Automotive Stamplings, Axis Bank, Biocon, Coromandel Engineering, Essel Propack, HIL, Indian Energy Exchange, JL Morison, Kirloskar Pneumatic, Oil Country, Rallis India, Reliance Capital, SBI Life Insurance, Shriram City Union Finance, Supreme Industries, Tata Elxsi, Tata Metaliks and YES Bank declaring their quarter and full-year results for the period ended March 2018.
500408 RALLIS 532215 SPMWY 505283 SHRIRAMCIT AXISBANK SUPREMEIND 500355 500135 500111 YESBANK AXB RELCAPITAL TATAMETALI ESSELPRO KIRLPNU 513434 532648 YYBKY 533167 COROENGG AXBKY 532498 AXBA STS TATAELXSI 509930

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...